A murine model of tuberculosis/type 2 diabetes comorbidity for investigating the microbiome, metabolome and associated immune parameters
- PMID: 34179725
- PMCID: PMC8212822
- DOI: 10.1002/ame2.12159
A murine model of tuberculosis/type 2 diabetes comorbidity for investigating the microbiome, metabolome and associated immune parameters
Abstract
Tuberculosis (TB) is one of the deadliest infectious diseases in the world. The metabolic disease type 2 diabetes (T2D) significantly increases the risk of developing active TB. Effective new TB vaccine candidates and novel therapeutic interventions are required to meet the challenges of global TB eradication. Recent evidence suggests that the microbiota plays a significant role in how the host responds to infection, injury and neoplastic changes. Animal models that closely reflect human physiology are crucial in assessing new treatments and to decipher the underlying immunological defects responsible for increased TB susceptibility in comorbid patients. In this study, using a diet-induced murine T2D model that reflects the etiopathogenesis of clinical T2D and increased TB susceptibility, we investigated how the intestinal microbiota may impact the development of T2D, and how the gut microbial composition changes following a very low-dose aerosol infection with Mycobacterium tuberculosis (Mtb). Our data revealed a substantial intestinal microbiota dysbiosis in T2D mice compared to non-diabetic animals. The observed differences were comparable to previous clinical reports in TB patients, in which it was shown that Mtb infection causes rapid loss of microbial diversity. Furthermore, diversity index and principle component analyses demonstrated distinct clustering of Mtb-infected non-diabetic mice vs. Mtb-infected T2D mice. Our findings support a broad applicability of T2D mice as a tractable small animal model for studying distinct immune parameters, microbiota and the immune-metabolome of TB/T2D comorbidity. This model may also enable answers to be found to critical outstanding questions about targeted interventions of the gut microbiota and the gut-lung axis.
Keywords: gut microbiota; host microbe interaction; infectious diseases; tuberculosis; type 2 diabetes.
© 2021 The Authors. Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures
Similar articles
-
Increased susceptibility to Mycobacterium tuberculosis infection in a diet-induced murine model of type 2 diabetes.Microbes Infect. 2020 Sep;22(8):303-311. doi: 10.1016/j.micinf.2020.03.004. Epub 2020 Mar 29. Microbes Infect. 2020. PMID: 32234542
-
16α-Bromoepiandrosterone as a new candidate for experimental diabetes-tuberculosis co-morbidity treatment.Clin Exp Immunol. 2021 Aug;205(2):232-245. doi: 10.1111/cei.13603. Epub 2021 Jun 1. Clin Exp Immunol. 2021. PMID: 33866550 Free PMC article.
-
Mucosal delivery of ESX-1-expressing BCG strains provides superior immunity against tuberculosis in murine type 2 diabetes.Proc Natl Acad Sci U S A. 2020 Aug 25;117(34):20848-20859. doi: 10.1073/pnas.2003235117. Epub 2020 Aug 10. Proc Natl Acad Sci U S A. 2020. PMID: 32778586 Free PMC article.
-
[Development of antituberculous drugs: current status and future prospects].Kekkaku. 2006 Dec;81(12):753-74. Kekkaku. 2006. PMID: 17240921 Review. Japanese.
-
The gut and lung microbiota in pulmonary tuberculosis: susceptibility, function, and new insights into treatment.Expert Rev Anti Infect Ther. 2023 Jul-Dec;21(12):1355-1364. doi: 10.1080/14787210.2023.2283036. Epub 2023 Nov 24. Expert Rev Anti Infect Ther. 2023. PMID: 37970631 Review.
Cited by
-
Gut microbiota: a crucial player in the combat against tuberculosis.Front Immunol. 2024 Oct 22;15:1442095. doi: 10.3389/fimmu.2024.1442095. eCollection 2024. Front Immunol. 2024. PMID: 39502685 Free PMC article. Review.
-
Intestinal microbiome dysbiosis increases Mycobacteria pulmonary colonization in mice by regulating the Nos2-associated pathways.Elife. 2024 Oct 16;13:RP99282. doi: 10.7554/eLife.99282. Elife. 2024. PMID: 39412514 Free PMC article.
-
Immunologic, metabolic and genetic impact of diabetes on tuberculosis susceptibility.Front Immunol. 2023 Jan 23;14:1122255. doi: 10.3389/fimmu.2023.1122255. eCollection 2023. Front Immunol. 2023. PMID: 36756113 Free PMC article. Review.
-
Impact of the gut-lung axis on tuberculosis susceptibility and progression.Front Microbiol. 2023 Jul 6;14:1209932. doi: 10.3389/fmicb.2023.1209932. eCollection 2023. Front Microbiol. 2023. PMID: 37485512 Free PMC article. Review.
-
Application of zebrafish in the study of the gut microbiome.Animal Model Exp Med. 2022 Dec;5(4):323-336. doi: 10.1002/ame2.12227. Epub 2022 Apr 12. Animal Model Exp Med. 2022. PMID: 35415967 Free PMC article. Review.
References
-
- WHO . Global Tuberculosis Report 2019. World Health Organization; 2019. https://apps.who.int/iris/bitstream/handle/10665/329368/9789241565714‐en.... Accessed December 19, 2019.
-
- Amberbir A. The challenge of worldwide tuberculosis control: and then came diabetes. Lancet Global Health. 2019;7(4):e390‐e391. - PubMed
-
- Ruslami R, Aarnoutse RE, Alisjahbana B, van der Ven AJ, van Crevel R. Implications of the global increase of diabetes for tuberculosis control and patient care. Trop Med Int Health. 2010;15(11):1289‐1299. - PubMed
-
- IDF . IDF Diabetes Atlas; 2019. http://www.diabetesatlas.org/. Accessed December 27, 2019.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical